Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's MYK-224?
MYK-224 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Diastolic Heart Failure (HFpEF)....
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's MYK-224?
MYK-224 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Diastolic Heart Failure (HFpEF)....
MYK-224 by Bristol-Myers Squibb for Diastolic Heart Failure (HFpEF): Likelihood of Approval
MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF). According to...